Quince Therapeutics, Inc.·4

Aug 31, 6:42 PM ET

Lamond David 4

4 · Quince Therapeutics, Inc. · Filed Aug 31, 2023

Insider Transaction Report

Form 4
Period: 2023-08-30
Lamond David
Director
Transactions
  • Purchase

    Common Stock

    2023-08-30$1.31/sh+41,026$53,7442,138,135 total(indirect: By Trust)
  • Purchase

    Common Stock

    2023-08-31$1.32/sh+41,026$54,1542,179,161 total(indirect: By Trust)
Holdings
  • Common Stock

    301,829
  • Common Stock

    (indirect: By Trust)
    1,734,722
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F2]Mr. Lamond is the trustee of Blue Devil Trust dated 12/03/2010 (the "Trust") and holds sole voting and dispositive power with respect to the shares held of record by the Trust.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]Mr. Lamond is the trustee of David A. Lamond Trust dated 2006 (the "2006 Trust") and holds sole voting and dispositive power with respect to the shares held of record by the 2006 Trust.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION